CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
The FDA has granted orphan drug designation (ODD) and RPDD to Arbor Biotechnologies' ABO-101, to treat primary hyperoxaluria ...
The US Food and Drug Administration (FDA) rejected three prior regulatory applications before granting approval.
EVA Pharma of Africa, DNA Script and Quantoom Biosciences have signed a MoU to establish the mRNA production platform in Egypt.
The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback